2025 Update of Cellular Immunotherapy for Plasma Cell Disorders
Despite progression-free survival in multiple myeloma (MM) patients extending to 17 years due to contemporary quadruplet induction therapies, there remains a necessity for novel products in the treatment of high-risk patients. BCMA, GPRC5D, FcRH5, SLAMF7, and TACI are the principal chimeric antigen...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Turkish Society of Hematology
2026-03-01
|
| シリーズ: | Turkish Journal of Hematology |
| 主題: | |
| オンライン･アクセス: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-24356 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|